MedTrace Logo

Autologous Bone Marrow Stem Cell Transplantation for Osteonecrosis in Sickle Cell Disease

NCT02448121 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-11-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow stem cells in sickle cell disease patients with osteonecrosis

Conditions

Interventions

PROCEDURE

Autologous bone marrow stem cell graft

All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.

Sponsors & Collaborators

  • Hospital Universitário Professor Edgard Santos

    collaborator OTHER

  • Oswaldo Cruz Foundation

    collaborator OTHER

  • Federal University of Bahia

    lead OTHER

Principal Investigators

  • GIldasio Daltro, MD · Federal University of Bahia

  • Vitor Fortuna, PhD · Federal University of Bahia

  • Roberto Meyer, MD · Federal University of Bahia

  • Radovan Borojevic, PhD · Federal University of Bahia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2018-07-31
Completion
2018-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02448121 on ClinicalTrials.gov